ON-TREATMENT LDL-C LEVELS WHEN ALIROCUMAB DOSE IS DECREASED FROM 150 TO 75 MG EVERY 2 WEEKS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM ODYSSEY

摘要

BACKGROUND: Alirocumab (ALI) is available in two doses, 75 and 150 mg (to be administered once every 2 weeks [Q2W]). ODYSSEY LONG TERM was a 78-week double-blind trial of ALI 150 mg Q2W versus placebo, as add-on to maximally tolerated statin ± other lipid-lowering therapy (LLT). Patients with heterozygous familial hypercholesterolemia (HeFH) who completed LONG TERM could enter the open-label ODYSSEY OLE (NCTO1954394) following an 8-week off-drug wash out period. From the start of OLE up to Week 8, all patients received ALI 75 mg Q2W (with their existing statin/other LLT). For the first time, this gives the opportunity to assess on-treatment LDL-C levels when the dose of ALI is decreased from 150 to 75 mg Q2W in a cohort of HeFH patients.